AiLNP
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 1
- MetiS and Eli Lilly sign AI-driven LNP delivery deal worth up to $1.1B
MetiS Therapeutics (7666.HK) announced on October 19 a strategic collaboration with Eli Lilly to research and discover new lipid nanoparticle (LNP) delivery solutions, including tissue-specific delivery for multiple treatment modalities. MetiS will use its AiLNP platform, driven by the NanoForge system, to develop next-generation LNP technology aimed at improving targeting and in-vivo distribution, while Lilly contributes drug discovery, development and commercialization resources. Under the terms, MetiS receives an upfront payment of more than $10 million and is eligible for up to $1.1 billion in development, regulatory and commercial milestones, plus tiered single-digit percentage royalties on annual net sales of collaboration products. DoNews, 36Kr and TMTPost described the deal as a platform-level collaboration, and 36Kr and TMTPost called it China's first generative-AI LNP platform export deal and the largest AI-driven extrahepatic LNP delivery collaboration; these ranking claims were not independently verified.
DoNews · 🔥 0
Experience and discussion from the community
Share my AiLNP experienceAsk about AiLNP
Nobody has shared their experience with AiLNP yet.